Summary
It has been demonstrated, both in breast cancer cell lines and in metastatic breast cancer patients with cutaneous lesions that could be biopsied, that treatment with interferon beta (IFN-B) can increase expression of both estrogen (ER) and progesterone receptors (PgR). To evaluate the efficacy and toxicity of the combination of IFN and tamoxifen, 33 metastatic breast cancer patients were treated with the following regimen: IFN-B, 6.0 million units intramuscularly IU 3 times a week for two consecutive weeks followed by IFN-B 6.0 million IU im 3 times a week with concomitant tamoxifen 20 mg orally daily. Patients were pre and postmenopausal with median age of 60 years, median ECOG PS of 0, either ER positive or unknown, and had not received prior hormone therapy for metastatic disease. Overall objective response was observed in 9 (27%) patients. Complete response was observed in 2 cases and partial response in 7 patients. Median duration of response was 7 months (range 2–10). A higher response rate was observed in patients with predominantly soft tissue disease (38%) compared to patients with either dominant bone (18%) or visceral lesions (17%). Toxicity was mild and reversible: low grade fever in 30% of patients and flu-like symptoms in 9% of cases. It appears that IFN-B does not improve the efficacy of tamoxifen in an unselected population of metastatic breast cancer.
References
Tamm I, Jasny BR, Pfeffer LM: Antiproliferative action of interferons. In: Pfeffer LM (ed) Mechanisms of Interferon Actions (Vol 2) CRC Press, Boca Raton, FL, 1987, pp 25–58
Baxter JD, Funder JW: Hormone receptors. N Engl J Med 301: 1149–1161, 1979
Tata JR: Modulation of hormone receptors. Nature (Lond) 269: 757–758, 1977
Sica G, Natoli V, Stella C, Del Bianco S: Effect of natural beta-inteferon on cell proliferation and steroid receptor level in human breast cancer cells. Cancer 60: 2419–2423, 1987
Sica G, Iacopino F, Lama G, Amadori D, Baroni M, LoSardo F, Malacarne P, Marchetti P, Pellegrini M, Zaniboni A, Robustelli della Cuna G: Steroid receptor enhancement by natural interferon-B in advanced breast cancer. Eur J Cancer 29: 329–333, 1993
Pouillart P, Palangie T, Jouvet M, Garcia-Giralt E, Fridman WH, Magdelenat H, Falcoff E, Billiau A: Administration of fibroblast interferon to patients with advanced breast cancer: Possible effects on skin metastasis and on hormone receptors. Eur J Cancer Clin Oncol 18: 929–935, 1982
Sica G, Iacopino F, Laura G, Lo Sardo F, Malacarne P, Zaniboni A, Marchetti P, Amadori D, Robustelli della Cuna G: Hormone receptor status: the role of biological response modifiers. Adv Oncol 1: 291–294, 1989
Goldstein D, Bushmeyer SM, Witt PL, Jordan VC, Borden EC: Effect of Type I and II interferons on cultured human breast cancer cells: Interaction with estrogen receptors and with tamoxifen. Cancer Res 49: 2698–2702, 1989
Kangas L, Nieminen AL, Cantell K: Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cellsin vitro. Med Biol 63 (4): 187–190, 1985
Hayward JL, Carbone PP, Heuson JC, Kamaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Cancer 39: 1289–1292, 1977
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981
Quesada JR, Gutterman JU, Hersh EM: Clinical and immunological study of beta interferon by intramuscular route in patients with metastatic breast cancer. Interferon Res 2: 593–599, 1982
Buzzi F, Brugia M, Rossi G, Giustini L, Scoponi C, Sica G: Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer. Anticancer Res 12: 869–872, 1992
Osborne CK, Yochmowitz MG, Knight WA: The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888, 1980
Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA: Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18: 165–179, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Repetto, L., Giannessi, P.G., Campora, E. et al. Tamoxifen and interferon-beta for the treatment of metastatic breast cancer. Breast Cancer Res Tr 39, 235–238 (1996). https://doi.org/10.1007/BF01806190
Issue Date:
DOI: https://doi.org/10.1007/BF01806190